What You Should Know:
– Caidya, a global mid-sized clinical research organization (CRO), announced today a $165 million strategic growth investment from funds managed by Rubicon Founders, a healthcare investment firm focused on building and growing transformative companies.
– The strategic investment will support Caidya’s continued expansion and its mission to accelerate the development of innovative therapies for unmet medical needs.
Fueling Growth and Strategic Acquisitions
Rubicon Founders’ investment will be instrumental in driving Caidya’s next phase of growth, enabling:
- Organic expansion: Further expanding Caidya’s global footprint and service offerings.
- Strategic acquisitions: Exploring potential acquisitions to enhance capabilities and accelerate growth.
This investment complements Caidya’s existing investors, which include leading global venture capital, private equity, and healthcare investors. David M. Glaccum, partner at Rubicon Founders, will join Caidya’s board of directors, bringing valuable expertise and guidance.
A Global CRO with a Patient-Centric Approach
With a presence in 23 countries and regions, Caidya offers full-service CRO capabilities and a strong commitment to partnering with biopharma sponsors. The company provides:
- Access to diverse patient populations: Facilitating global clinical trials and accelerating drug development.
- Specialized clinical research services: Expertise in oncology, hematology, rare and pediatric diseases, and other therapeutic areas with significant unmet needs.
- Strategic partnership model: Delivering customized solutions and white-glove service to support biopharma clients.
“We are extremely excited to get Rubicon Founders’ support as Caidya embarks on our next phase of growth and transformation. Rubicon Founders will bring tremendous expertise and resources to accelerate our global growth, in full alignment with our aspiration to be the leading mid-sized CRO serving biopharma innovation across the Americas, Europe, and Asia-Pacific,” said Caidya’s Chief Executive Officer, Barbara Lopez Kunz.
